TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03526874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 4% Topical Application Cream [LMX 4]
Description: Run-in Step: All subjects receive 32 mg (4 cm ribbon of cream) applied, bilaterally, over greater occipital nerve.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine 4% Topical Application Cream [LMX 4]
Description: Run-in Step: All subjects receive 32 mg (4 cm ribbon of cream) applied, bilaterally, over greater occipital nerve.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 2 mg/mL Injectable Solution
Description: Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the active treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the comparator.
Study: NCT03086967

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double-lumen balloon catheter
Description: introduction of catheter into cervix for ripening prior to induction of labor following standard of care practices
Study: NCT01477450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylinder oxygen delivery
Description: Oxygen delivery from an oxygen cylinder
Study: NCT01955486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flight simulation
Study: NCT00988390

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive-behavioral, small-group format sessions
Description: The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
Study: NCT00914212

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose placebo to sibutramine in two of three treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: sibutramine
Description: Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.
Study: NCT04426656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone application
Description: The mini-app (used in Part 2) has four main functions:~1. a knowledge center that contains a series of HIV-, sexual health-, and PrEP-related educational articles in Chinese;~2. an HIV self-test toolkit ordering system that allows users to order a finger-prick HIV rapid test toolkit and shipped to home for free (one piece at a time);~3. an asynchronous message function that allows users to chat with a study staff (C.Li); and~4. a user profile page where users can manage all HIV test orders.
Study: NCT05737147

Intervention type: DEVICE
Intervention: Zero Heat Flux Thermometer
Description: Comparison of the accuracy and precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature Measurement
Study: NCT00627445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 500 - 2000 mg, once, twice or three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 500 - 2000 mg, once, twice or three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch
Study: NCT04505540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bridge Clinic
Description: Specialized addiction bridge clinic
Study: NCT01722227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04136119

Intervention type: OTHER
Intervention: questionnaire
Description: survey exploring practice of vitamin and micronutrient supplementation
Study: NCT03959319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement Pattern Training
Description: Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
Study: NCT01102283

Intervention type: DEVICE
Intervention: Evolution(R) Colonic Stent
Description: Palliative treatment of colonic obstruction or strictures caused by malignant neoplasms and to relieve acute large bowel obstruction prior to colectomy in patients with malignant strictures.
Study: NCT04317027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Fighting Clothing
Description: VO2max test Clothing examination- 2-hour walk in 6 kph/4% elevation under 30 degrees Celsius and 60% relative humidity
Study: NCT04221243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed space maintainer by NextDent Ortho Rigid
Description: Biocompatible 3D printing material

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Band and Loop
Description: metal space maintainer
Study: NCT04672252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD Oral Disintegrating Tablet (ODT)
Description: Cohort 1: CBD ODTs to be administered with routine post-operative pain management regimen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ODT
Description: Cohort 2 will not receive CBD; but a visually indistinguishable placebo ODT instead.~The resident physician, physician assistant, anesthesiologist, surgeon and study team members will remain blinded. Additionally, all patients will receive a traditional upper extremity interscalene block as per routine.
Study: NCT00334074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine and Cytarabine
Description: Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity
Study: NCT01582854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actovegin
Description: Actovegin solution for infusion and Actovegin tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
Study: NCT00977080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)
Study: NCT02286674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet (Audio/Visual Device)
Description: Subjects will be given a tablet to use before surgery
Study: NCT03952741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Study: NCT02242240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol once daily
Study: NCT00977080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)
Study: NCT03964337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 40 mg by mouth daily for 4 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Radical prostatectomy as part of routine medical care.
Study: NCT01015196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zavedos
Study: NCT02242240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium once daily
Study: NCT01015196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerubidine
Study: NCT01253733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MD2ME
Description: The goals of the MD2Me intervention include increasing disease self-efficacy, disease knowledge, and the ability to control one's disease independently. The intervention includes an 8-week web program with weekly behavioral skills, topics on how to navigate the healthcare system, lifestyle tips, a Discussion Board, and text messages.
Study: NCT02421393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised exercise training
Description: Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of weight bearing exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity.
Study: NCT00820430

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
Study: NCT02242240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00229619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (Rituxan) 375mg/m2 intravenous infusion. The infusion will be once every week for a total of 4 doses.
Study: NCT03886623

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4-day systematic oral hygiene
Description: he intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery-operated Oral-B Pro-Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro-Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
Study: NCT05466903

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early diet opening
Description: Effects of early dietary recovery after colon polypectomy and colonoscopic mucosal resection on postoperative hemorrhage in patients
Study: NCT02488694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m² i.v. on d1 of each 21-day cycle
Study: NCT00570661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: ITF2357 orally administered at the cumulative daily dose of 1.5 mg/kg, achieved by administration of different dose strengths identifiable by different colours.
Study: NCT02152397

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-led brief intervention (TBI)
Study: NCT03964337

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: Radical prostatectomy as part of routine medical care.
Study: NCT03071666

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cobalamin
Description: Vitamin supplment tablet containing 50µg cobalamin
Study: NCT01687673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib:
Description: 200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
Study: NCT01431300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadofosveset
Description: Intravenous administration of the specified dosage of gadolinium contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadofosveset
Description: Intravenous administration of the specified dosage of gadolinium contrast agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadofosveset
Description: Intravenous administration of the specified dosage of gadolinium contrast agent
Study: NCT00445588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 150mg Given orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: 400mg Given orally twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02241889

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump therapy
Description: Subject's own insulin pump will be used to manage blood glucose.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop Artificial Pancreas Controller
Description: Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
Study: NCT05747404

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: - Develop new parameters of FTR severity that take into account the lower momentum of the tricuspid regurgitant jet (compared with the mitral regurgitation jet), the complex anatomy of the regurgitant orifice, and both the intra-beat and respiratory variation of the regurgitant volume
Study: NCT04082247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The education and training of early childhood educators and their intervention on children
Description: A 24-week cluster randomized trial will be developed, with the childcare being the randomization unit. Training sessions will be conducted for all early childhood educators in the intervention group. The control group will receive the Portuguese standard education and at the end of the intervention this group will also receive the initial training given to the intervention group, so that they can later also implement the intervention. At the end of the intervention, all early childhood educators and parents/guardians will have access to the intervention outcomes.
Study: NCT02241889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop Artificial Pancreas Controller
Description: Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
Study: NCT03706651

Intervention type: DEVICE
Intervention: Infants hospitalized in health facilities performing Tele-expertise
Study: NCT04034953

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Faecal Immunochemical Test
Description: Faecal Immunochemical Test detects if there is any hemoglobin presents in stools, so even tiny amount of blood in stool can be found.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Prostate-Specific Antigen Test
Description: PSA blood test is used to measure the level of PSA in blood. When the PSA level is higher than normal, it may represent prostate cancer or benign prostate hyperplasia. Patient who have high PSA level should receive additional tests.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mammogram
Description: Each sides of breast will be taken imaging in 2 different views.The breast will be pressed between 2 plastic plates to flatten and spread the breast tissue for clear imaging.
Study: NCT01456975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic valve reimplantation using Valsalva prosthesis
Description: Aortic valve reimplantation (David procedure)using Valsalva prosthesis
Study: NCT01356173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0349
Description: Oral escalating dose
Study: NCT02982720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously.
Study: NCT02054858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
Study: NCT00904787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Description: capsule, dose escalation, taken orally, daily in 28 day cycles
Study: NCT01295268

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emu Oil
Description: Subjects will apply a specified amount of emu oil daily to area.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inert oil
Description: A specified amount of inert oil will be applied daily to area.
Study: NCT01871103

Intervention type: PROCEDURE
Group type: OTHER
Intervention: The dorsal homodigital island flap
Description: The dorsal homodigital island flap is used for tissue reconstruction in different regions of the finger.
Study: NCT03483532

Intervention type: DIETARY_SUPPLEMENT
Intervention: Lit Control pH Up
Description: dietary supplement based on citrate, saponins, magnesium, zinc and vitamin A
Study: NCT03886623

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care oral care
Description: Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol-Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
Study: NCT04597151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Attend diet education sessions
Study: NCT00294281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) Therapy
Description: The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
Study: NCT00814216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAV680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo for QAV680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Study: NCT02591771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline
Description: i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
Study: NCT00827931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid + Standard of Care
Description: Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
Study: NCT06046352

Intervention type: PROCEDURE
Intervention: Electrophysiological study (and ablation when appropriate)
Description: Electrophysiological study (and ablation when appropriate)
Study: NCT01612845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic repair without platelet rich fibrin
Description: after the tendon is repaired, no additional procedures are performed and no PRF is administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF (vivostat ®) administration after rotator cuff repair
Description: 7cc. of autologous PRF are locally administered to the repair site after reconstruction of the rotator cuff